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Abstract
This study evaluates the embryotoxicity of dithienylethene-modified peptides upon photoswitching, using 19 analogues based on
the β-hairpin scaffold of the natural membranolytic peptide gramicidin S. We established an in vivo assay in two variations (with ex
vivo and in situ photoisomerization), using larvae of the model organism Danio rerio, and determined the toxicities of the peptides
in terms of 50% lethal doses (LD50). This study allowed us to: (i) demonstrate the feasibility of evaluating peptide toxicity with
D. rerio larvae at 3–4 days post fertilization, (ii) determine the phototherapeutic safety windows for all peptides, (iii) demonstrate
photoswitching of the whole-body toxicity for the dithienylethene-modified peptides in vivo, (iv) re-analyze previous structure–tox-
icity relationship data, and (v) select promising candidates for potential clinical development.
Introduction
Biologically-active peptides as a class of chemotherapeutic
compounds are uniquely positioned between traditional small
organic molecule drugs and high-molecular weight biologics
[1,2]. Since recent breakthroughs in peptide synthesis technolo-
gy [3,4] have enabled peptide production at industrial scales,
the exploration of therapeutic peptides as potential drugs is
rapidly developing [4-6]. It has been shown that peptide drugs
are less immunogenic than biologics and can hit the “undrug-
gable” space of molecular targets [2,7,8]. As a result, the
market for peptide drugs (e.g., hormones, receptor antagonists,
anticancer, or antibiotic agents) grows faster than that of many
other chemotherapeutics [9]. Significant general disadvantages
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Figure 1: DAE photoswitch and photoswitchable peptides explored in this study. (A) The reversible photoisomerization of the dithienylethene photo-
switch core. (B) Photoconversion between ring-open and ring-closed photoforms of DAE-derived peptides. (C) Structures of the non-photoswitchable
cytotoxic peptide GS (1), and one of our first photoswitchable prototypes 2 in the ring-open photoform.
of peptides as pharmacological agents are their poor oral
bioavailability, low plasma stability in vivo, limited under-
standing of their mechanisms of action, and high in vivo toxici-
ty. The former two drawbacks are being adequately resolved [9]
(e.g., by modifying the peptide backbone [10], macrocycliza-
tion [11], or by use of unnatural amino acids [12]), and mecha-
nistic understanding of the relevant molecular mechanisms is
gradually improving [13]. However, the safety consideration
still poses a considerable challenge. Hence, the understanding
and decreasing of the in vivo toxicity of peptides is of para-
mount importance for their development as drugs.
In recent years, photopharmacology [14-16] has emerged as a
successful approach to enhance spatiotemporal selectivity of
chemotherapeutics, decreasing the overall toxicity and increas-
ing the safety of drugs. Various compound classes are currently
being explored as photopharmacology agents [16-21], includ-
ing peptides [19-21]. The idea behind photopharmacology is
based on the design and use of drugs containing a reversibly
photoisomerizable fragment (“molecular photoswitch”) as part
of their structure. Importantly, the photoisomerizable fragment
should – in one of its photoforms – destroy or mask the pharma-
cophore (the drug is “switched OFF”), whereas the other photo-
form should restore the biological activity of the active element
(the drug is “switched ON”). Correspondingly, an inactive drug
(the OFF photoform) can be safely administered, and subse-
quently it can be locally activated for the therapy (converted to
the ON photoform) by applying light of a specific wavelength,
precisely at the desired site of action. Spatiotemporal resolution
of such light-mediated drug delivery is limited mainly by the
technical characteristics of the medical devices used for light
application and by the light propagation in tissues.
Among several known photoswitches [18] that are being used in
peptides [19-23], diarylethenes (DAE) have increasingly at-
tracted attention in recent years [22,23]. Photoswitchable DAE-
derived molecules offer several advantages for medical applica-
tions, as their photoforms are thermally irreversible and highly
fatigue resistant [24-26]. Light-induced reversible pericyclic
reactions toggle the structure of DAE between a flexible ring-
open isomer and a planar rigidified ring-closed form
(Figure 1A). Irradiation of the ring-open isomer with UV light
(<400 nm) generates the ring-closed isomer, while irradiation
with visible light (>400 nm) converts the ring-closed isomer
back to the ring-open photoform (Figure 1B), thereby affecting
the structure and flexibility of the immediate molecular sur-
rounding.
We have constructed a number of DAE-containing peptides by
incorporating a DAE photoswitch into the backbone of grami-
cidin S (1, GS), which is an intrinsically biostable cyclic
peptide, as exemplified by one of our first prototypes com-
pound 2 (Figure 1C). This natural antimicrobial agent has an
amphipathic structure, whose functional mechanism is attri-
buted to the permeabilization of bacterial membranes, with con-
siderable side-effects also on eukaryotic cell membranes
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[27,28]. Compared to the ring-closed (deactivated, OFF) photo-
form, the ring-open (active, ON) isomer of 2 indeed displayed a
much stronger in vitro toxicity against several tumor cell lines
[29,30]. Using the photoswitchable analogue 2 in an allograft
mouse model, the first in vivo photopharmacology application
for a DAE-derived peptide as an anticancer agent has been
demonstrated [29]. In order to optimize 2, we have recently per-
formed a structure–activity relationship (SAR) study using a
library of photoswitchable derivatives of 2 [30]. The library
contained 29 compounds grouped into several series: with
natural amino acid mutations affecting the amphipathicity
(series i), with point mutations that modulate polarity and con-
formational stability of the β-structural elements (series ii), with
backbone N-alkylation and side-chain hydroxylation modifica-
tions (series iii), with macrocycle ring-size variations (series
iv), and with macrocycle homodimerization (series v). We
systematically screened the ring-open and ring-closed photo-
forms of all 29 compounds in vitro, using a range of cellular
toxicity assays (against Gram-positive bacteria, Gram-negative
bacteria, HeLa cells, and human erythrocytes) and were able to
rationalize the specific impact of our modifications onto cell
selectivity indices. Though all compounds demonstrated
distinctly different cell toxicities in the ring-open and the ring-
closed photoforms, we noticed that there was generally a poor
correlation between the antibacterial activity on the one side,
and the cytotoxicity against HeLa cells on the other side, and
erythrocytes as a third scenario. Different compounds could
thus be regarded as potential leads for chemotherapy of either
infectious diseases caused by Gram-positive or -negative
bacteria, or for anticancer applications. We hypothesized that
the lack of correlation between cell types might not only reflect
different mechanisms of killing (possibly even within any pair
of isomers), but that it may also be due to unique differences of
erythrocytes compared to other somatic cells. Although easily
measured, hemolytic activity gives only a rough estimate of
toxicity for peptide therapeutics. Erythrocytes are terminally
differentiated non-adherent organelle-free cells, densely packed
with oxygen-carrying proteins; their homeostasis and pharma-
cokinetics are highly specialized, and many molecular targets
are absent in them [31].
Aiming at applications of photoisomerizable drugs in human
healthcare, investigators cannot be limited to in vitro toxicity
assays. Furthermore, preclinical drug development programs
specifically require the inclusion of in vivo toxicity studies
using vertebrate animal models. (For example, toxicity studies
of anticancer chemotherapeutics are requested by the Interna-
tional Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use (ICH) to include at least
two mammalian species, whereby one of them must be a non-
rodent [32]). Comprehensive in vivo toxicity studies are obvi-
ously lengthy, significantly more expensive than in vitro assays,
and are hampered by strict bioethics regulations. We therefore
looked for an alternative toxicity assay that would be as techni-
cally simple as hemolysis, and at the same time would make the
data more relevant to human toxicity. Hence, we selected the
zebrafish embryotoxicity assay as a potential compromise. Due
to their small size, cheap husbandry and maintenance, fast
embryogenesis, extracorporeal development, known genome
and accessibility of several thousand transgenic lines [33],
zebrafish (Danio rerio) is an excellent model for develop-
mental biology and phenotypic genetics [34]. The zebrafish
species are attractive to utilize them in toxicity studies due to
several reasons. Optimum maintenance and breeding condi-
tions for D. rerio are well described in the literature [35], as
well as complete details of its embryogenesis [34]. Further-
more, the vertebrate body plan of the zebrafish is, in its basic
structure, similar to mammals [36,37], and up to 80% of the
known human drug targets are present in the D. rerio genome
[38]. Since 2005, a zebrafish embryotoxicity test is used as a
standardized ISO assay for sewage water testing in Germany
[39,40]. Due to its manifold advantages, zebrafish larvae could
be used as a cost-effective vertebrate animal model, yet sophis-
ticated enough for pharmacological toxicity evaluations, espe-
cially for preclinical drug candidate screenings. However, to the
best of our knowledge, such applications for therapeutic
peptides are still sparse [41-45]. Notably, zebrafish embryos are
transparent, which makes them ideal for in vivo manipulation of
photosensitive compounds [46]. This has been advantageously
used by other authors in studies of azobenzene-containing
photoswitchable bioactive agents [47-50]. Finally, according to
the recent edition of EU directive 2010/63/EU, zebrafish em-
bryos of up to 5 days post fertilization (dpf), as the larvae are
still feeding on the yolk [51], are excluded from the legislation
governing animal testing, i.e., experiments do not require
ethical approval.
In this study, we selected 19 photoswitchable DAE-modified
cytotoxic peptides from our previous SAR evaluation [30] and
established with them the D. rerio embryotoxicity assay. For
each photoswitchable peptide, we determined the lethal dose of
both photochromic forms, using two assay variations, and these
in vivo toxicity values could then be compared with the known
in vitro cytotoxicities.
Results and Discussion
All peptides (Table 1) were synthesized as was previously de-
scribed [30] and initially handled as ring-open photoforms
under ambient (visual, vis) light conditions. Each of the ring-
open photoforms was converted into the ring-closed photo-
forms by UV irradiation in a solution of denaturing agents,
reproducing previously documented results [29,30,52]. All
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Table 1: Nomenclature, sequences, molecular masses of the peptides synthesized and explored in this study. The photoswitchable peptides are
grouped in series (i–v) according to their original design [30].
Peptide Linear sequencea
Molecular mass, m/z
calculated measured
1 fPVOLfPVOL 1141.4 1141.2
2 DAE-VOLfPVOL 1280.7 1280.1
analogues with point mutations affecting amphipathicity (series i)
3 DAE-VOLfPVOA 1238.6 1238.1
4 DAE-AOLfPVOA 1210.6 1210.1
5 DAE-OOLfPVOL 1295.7 1295.1
mutations affecting polarity and stability of β-structures (series ii)
6 DAE-TOVfPVOV 1254.6 1254.1
7 DAE-AsniPr-OVfPVOV 1309.7 1309.3
8 DAE-DabiBu-OVfPVOV 1323.7 1323.3
9 DAE-IOLpPIOL 1258.7 1258.5
analogues with N-alkylation and hydroxylation modifications (series iii)
10 DAE-IOIf-LeuN-Me-LOI 1338.8 1338.8
11 DAE-IOLf-LeuN-Bu-IOL 1380.9 1380.4
12 DAE-LeuOH-OVfPVOV 1282.7 1282.3
13 DAE-VOVfP-LeuOH-OV 1282.7 1282.4
14 DAE-VOVfPVO-LeuOH 1282.7 1282.4
15 DAE-LeuOH-OVfP-LeuOH-OV 1312.7 1312.4
analogues with extended macrocycles (series iv)
16 DAE-VKLKVfPLKVKL 1777.4 1776.2
17 DAE-VKLKVfPLkVKV 1763.3 1762.2
18 DAE-VKLKVfPKLVKV 1763.3 1762.2
“click”-chemistry connected homodimers (series v)
19 DAE-LeuOH-OLf-OrnN3N-Me-VOLb 2773.5c 2773.1c
20 DAE-OrnN3-OLfPVOLb 2681.4c 2681.0c
aCanonical amino acids and ornithine (designated O) are given in one-letter code. Lower case letters are for amino acids with ᴅ-configuration. Non-
canonical amino acids are presented by three-letter code. Superscript indices N-Me and N-Bu, next to a three-letter abbreviation, indicate N-methyla-
tion and N-butylation, respectively. LeuOH = (2S,3R)-β-hydroxyleucine; AsniPr = Nγ-isopropylasparagine; DabiBu = Nγ-isobutyryldiaminobutyric acid;
OrnN3 = L-δ-azidoornithine; DAE photoswitching fragment = 4-(2-(5-((ʟ-prolyl-2-methylthiophene-3-yl)cyclopent-1-en-1-yl)-5-methylthiophene-2-
carboxyl); bmonomers (as listed here) were dimerized through azides of the azidoornithines via propargyl ether by means of Cu(I)-catalyzed “click”
reaction [29]; cmolecular masses are for final ether-conjugated dimers.
studied compounds were prepared in >95% purity using prepar-
ative-scale high-performance liquid chromatography (HPLC).
To establish the assay for screening the photoswitchable
peptides, we first studied the toxicity of our prototype 2 by
varying the assay conditions. The parent peptide GS 1 was used
as a control. Although the parent 1 does not contain a photo-
switchable moiety, it was treated throughout the assay in the
same fashion as 2, in order to account for both (i) the light ap-
plication effects as well as (ii) the expected [53] developmental
changes of the embryos during the experiment. We measured
the doses causing the death of 50% embryos (LD50). We tested
two different assay variations: in one version, the LD50(open)
was determined after direct application of 1 or of the ring-open
form of 2. In the other variant, the photoswitchable peptide was
applied in the ring-closed photoform in the darkness, its
LD50(closed) was recorded, and then in situ illumination (“pho-
toactivation”) was applied to switch into the ring-open photo-
form and obtain the respective LD50(opened) values (see
Figure 2 for the study design and the killing curves).
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Figure 2: Two versions of the D. rerio embryotoxicity assay for DAE-modified peptides: timelines, peptide photostates, ages of larvae, and definitions
of the measured characteristics. (A) Direct application of the non-photoswitchable parent GS 1 or of the ring-open photoform of our prototype 2, and
the corresponding killing curves for 1 (C, top, black) and 2 (C, bottom, red). (B) “Photoactivation” assay: initial application of the ring-closed photoform,
incubation in darkness, followed by in situ photoconversion into the ring-open(ed) photoform, with the corresponding killing curves for 1 (D, top) and 2
(D, bottom, green for ring-closed, red for ring-open isomers). The latter panel illustrates the “phototherapeutic safety window” (green arrow) as the
difference in toxicity between the ring-closed and the ring-open isomers upon photoactivation.
Each time, 12–15 or 18–20 zebrafish embryos at 3 dpf were
treated by applying the corresponding peptide dissolved in
dimethyl sulfoxide (final dimethyl sulfoxide concentration
was 0.2%). Double-concentrated peptide stock solutions
(64–512 µg/mL) were prepared by weighing lyophilized
peptides, dissolving in 10% dimethyl sulfoxide and construct-
ing two-fold dilution series with ten–eleven dilution steps. In
the photoconversion experiments, in order to prevent spontane-
ous photoswitching of the ring-closed peptides by vis light,
zebrafish embryos and peptides were kept in the dark before the
first readout, and the vials were sealed to avoid evaporation of
the embryonic medium (E3) at prolonged incubation times.
After the first screen, without exchanging any solution, the vials
with embryos and ring-closed photoforms were exposed to
intense illumination for 10 min (LUMATEC Superlite 410 light
source, λ = 570 nm, irradiance approximately 20 mW/cm2).
Mortality was then determined under ambient light conditions
at 1 h and 24 h after the illumination procedure.
As shown in Figure 2C, the control 1 (non-switchable parent)
and the ring-open isomer of our first prototype 2 displayed very
similar LD50 values upon direct application. After 24 h, 50% of
Beilstein J. Org. Chem. 2020, 16, 39–49.
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Table 2: Toxicities and LD50(closed)24h/LD50(open)24h ratios for the photoswitchable peptides. The peptides are grouped in series (i–v) according to
their original design in [30].
Peptide Toxicities at different conditions, µg/mL ± STDa LD50(closed)24h/LD50(open)24h
ratio
LD50
(open)1h
LD50
(open)3h
LD50
(open)24h
LD50
(closed)24h
LD50
(opened)1h
LD50
(opened)24h
1 2.8 ± 2.7 2.0 ± 3.0 2.4 ± 0.2 – – – –
2 2.7 ± 1.0 1.7 ± 1.1 2.1 ± 0.3 34.2 ± 12.2 3.3 ± 0.7 0.7 ± 1.3 16.3
analogues with point mutations affecting amphipathicity (series i)
3 9.3 ± 7.8 4.8 ± 3.9 4.7 ± 0.1 31.1 ± 4.2 9.5 ± 1.3 6.2 ± 0.6 6.6
4 69.8 ± 10.5 40.6 ± 11.2 19.0 ± 1.3 197.7b 51.0 ± 7.7 12.9 ± 1.9 10.4
5 4.8 ± 2.2 2.8 ± 1.9 3.3 ± 0.7 8.1 ± 1.0 8.1 ± 1.0 5.3 ± 0.5 2.5
mutations affecting polarity and stability of β-structures (series ii)
6 30.8 ± 15.0 13.2 ± 13.3 8.6 ± 0.0 196.9b 20.6 ± 1.7 6.3 ± 2.3 22.9
7 15.9 ± 4.3 8.7 ± 9.1 5.8 ± 0.4 266.4b 18.2 ± 4.6 3.0 ± 2.5 45.9
8 12.0 ± 0.8 5.7 ± 0.4 3.9 ± 1.5 472.9b 9.6 ± 5.6 3.0 ± 2.7 121.2
9 2.0 ± 1.1 2.1 ± 0.8 1.6 ± 0.3 9.1 ± 2.7 2.2 ± 0.5 0.8 ± 0.1 5.7
analogues with N-alkylation and hydroxylation modifications (series iii)
10 1.3 ± 1.5 1.0 ± 0.6 1.0 ± 0.6 9.5 ± 0.1 2.2 ± 1.0 1.3 ± 1.5 9.5
11 3.0 ± 1.8 2.4 ± 0.7 1.6 ± 0.1 4.4 ± 0.2 4.0 ± 0.3 3.0 ± 1.0 2.8
12 9.2 ± 1.1 6.7 ± 0.4 3.6 ± 0.5 77.0 ± 19.4 6.2 ± 0.0 2.1 ± 1.0 21.4
13 4.8 ± 3.8 4.3 ± 3.8 2.2 ± 1.0 45.0b 6.4 ± 0.4 3.4 ± 0.5 20.5
14 8.1 ± 2.0 6.2 ± 0.7 2.0 ± 0.0 50.4 ± 27.2 9.1 ± 4.2 4.6 ± 2.0 25.2
15 36.5 ± 2.1 14.1 ± 6.0 7.2 ± 3.8 56.1 ± 12.2 22.9 ± 0.2 7.2 ± 0.7 7.8
analogues with extended macrocycles (series iv)
16 3.1 ± 1.0 1.6 ± 0.0 6.0 ± 0.1 5.6 ± 0.5 5.2 ± 0.5 3.8
17 10.5 ± 5.8 3.2 ± 0.2 9.9 ± 0.1 9.9 ± 0.1 9.4 ± 0.7 3.1
18 0.9 ± 0.4 0.4 ± 0.2 12.3 ± 1.5 12.3 ± 1.5 12.3 ± 1.5 30.8
“click”-chemistry connected homodimers (series v)
19 2.7 ± 1.7 1.2 ± 0.3 4.8 ± 0.3 4.7 ± 0.5 4.3 ± 1.3 4.0
20 3.7 ± 1.9 1.5 ± 0.0 10.7 ± 0.1 8.4 ± 3.3 3.5 ± 0.6 7.1
aSTD = standard deviation; bSTD was not calculated, the measurement was performed once.
embryos had died at a concentration of 2.4 ± 0.2 µg/mL GS 1
and 2.1 ± 0.3 µg/mL ring-open 2. With increasing incubation
time, lower concentrations were expected to achieve compa-
rable mortality; however, the difference between 1 h and 24 h
incubation was low for both peptides (Table 2).
The photoactivation assay, in which two photoisomers of 2
were tested, shows the anticipated difference between the non-
photoswitchable 1 and the photoswitchable 2 (Figure 2D and
Table 2). For 1, the dose-dependent mortality before and after
illumination was very similar, with only marginal deviation
caused by prolonged incubation time. In contrast, 2 displayed
an about 16-fold decrease in the LD50 value after in situ photo-
activation. This difference indicates that the ring-open isomer of
2 indeed possesses a higher toxicity than the ring-closed isomer,
and it demonstrates in vivo photoswitching of the whole-body
toxicity.
Since the determined LD50 values were practically identical in 3
independent experiments, both assays were used to evaluate the
entire library of 19 photoswitchable peptides (see Table 2).
Overall, the two assay versions gave comparable LD50 values
for each of the tested peptide, namely LD50(open)1h vs
LD50(opened)1h, and LD50(open)24h vs LD50(opened)24h. An
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exception was noted for the elongated analogues 16–18, where
the light-generated ring-opened forms did not restore the activi-
ty levels observed in the direct application experiment. This be-
havior could be explained by a decreased proteolytic stability of
these lysine-rich analogues. For the remaining 16 photoswitch-
able peptides, only minor differences in LD50 values between
the two types of assays were found. These slight discrepancies
are attributed to the different developmental stages of the em-
bryos in the two assays. In the direct activation assay the
zebrafish embryos were at 3 dpf, whereas in the photoactiva-
tion assay they were at 4 dpf when the ring-closed isomer was
converted into the ring-open isomer and subsequently measured
at 5 dpf. Also, shielding the embryos for 24 h from light expo-
sure might affect embryogenesis and sensitivity of the larvae
[53]. Furthermore, the uptake and accumulation of the ring-
closed and ring-open isomer could be different in each case.
Due to photochemical properties of DAE, a realistic DAE-
derived in vivo photopharmacology agent should have a low
toxicity in the ring-closed form and a high activity in the ring-
open form [29,30]. Therefore, analysis relating (undesired) tox-
icity of the closed form to the (desired) activity of the open
form is crucial for the drug candidate assessment. To compare
results from different assays and to visualize activity relations
of the two photoforms, phototherapeutic indices (e.g.,
HC50(closed)/IC50(open) and correlation analysis scatter plots
are convenient approaches [30]. Analyzing our data, it was
interesting to see that the structure–toxicity relationships turned
out to be more complicated than it had initially been anticipat-
ed and implemented in the original design of the peptide series.
Nonetheless, except for the peptides in series iv (16–18, with
increased charge densities) and one of the homodimers (19), the
difference in activity between the ring-open and the ring-closed
photoforms was significant. In all cases, the ring-open states
were more active than the corresponding ring-closed photo-
forms. For approximately half of the peptides (2, 7, 8, 9–13, and
20), the ring-open photoforms were even more toxic than the
non-switchable parent compound 1. For our prototype peptide
2, the ratio LD50(closed)24h/LD50(open)24h was equal to 16.3.
The largest drop in toxicity was observed for the inactive forms
of peptides 4, 6, 7 and 8 (LD50(closed)24 ≥ 200 µg/mL), fol-
lowed by the analogs with hydroxyleucine side chains 12, 13,
14, and 15 (with values in the range of 50–80 µg/mL). This
trend, naturally, translates into the safety windows being the
largest for these compounds. Peptides 7, 8, and – surprisingly –
18, significantly surpassed the safety window of the original
prototype 2.
The data in Table 2 reveals several structure–toxicity correla-
tions. Both of the tested dimers (19, 20) showed relatively inef-
ficient photoactivation. Given that 19 and 20 were observed to
photoisomerize readily between the ring-closed and ring-
opened isomers, we can presume that homodimerization may
affect the way in which the peptides interact with their molecu-
lar targets, or it may compromise their long-term biostability.
Likewise, an elongation of the β-sheet core and an increase in
cationic charge density (peptides 5, 15–17) was seen to de-
crease the photoactivation efficiency in vivo. The correspond-
ing LD50 values indicate that an uncharged polar amino acid
residue next to the DAE (compounds 6, 7, 8) and the presence
of hydroxyleucine residues (12, 13, 14) improve the photoacti-
vation efficiency compared to compound 2. Even though this
prototype 2 already had quite a large phototherapeutic safety
window (the ratio LD50(closed)24h/LD50(open)24h is 16.3), the
new mutants showed even higher safety, the best being peptide
8 (with a ratio LD50(closed)24h/LD50(open)24h of 121).
We have also analyzed the correlation between the empirical
low-pH hydrophobicity of the peptides (as assessed from the
retention times in reversed-phase HPLC) and toxicity against
zebrafish embryos. Independent on the photoisomeric state and
the type of toxicity assay, decreasing polarity of the peptides is
accompanied by an increase in toxicity against zebrafish em-
bryos (compare Figure 3A and 3B). Within the different series
of peptides (the series are marked with different colors in
Figure 3 for clarity) we get almost linear toxicity–hydrophobici-
ty correlations in most cases, and all the outliers are readily
explainable. For instance, in Figure 3A the peptides 19 and 20
are from series v (homodimers), compounds 16–18 have larger
(extended) macrocycles and together with 5 possess a higher net
charge and charge density than the rest of the peptides. For the
most hydrophobic peptide 11 in the ring-open form, which
deviates from the general trend, we observed a very low water
solubility and tendency to aggregate.
As can be seen from Figure 4, the toxicity against zebrafish em-
bryos is higher than hemolysis for the majority of the ring-open
isomers and for all ring-closed photoforms. This result suggests
that the lysis of red blood cells may not be the leading cause of
in vivo toxicity for these membranolytic peptides.
Based on the results described above, we wondered whether the
cytotoxicity against epithelial cells should be considered as an
important safety aspect for applications in humans, and whether
it should be monitored in preclinical evaluation of this type of
chemotherapeutics. It is known, that compounds from the sur-
rounding media are absorbed by the zebrafish mainly through
the skin and gills at embryonic stages and through the digestive
system during later larval stages [54], which points to epithelial
cells as the immediate target and should correspond to the
dermal route of administration or other through-epithelium
paths in human applications. Notably, it has been shown that
Beilstein J. Org. Chem. 2020, 16, 39–49.
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Figure 3: The in vivo toxicity against D. rerio embryos appears to be correlated with the empirical hydrophobicities of GS 1 and its photoswitchable
analogues 2–20. LD50 values are plotted against the HPLC (C18) retention times upon elution with a standardized linear water/acetonitrile gradient:
both, for the ring-closed photoforms (A, filled circles), as well as for the ring-open photoforms (B, open circles). The compound numbers are shown
next to the data points. Values for the parent peptide 1 are shown as black filled circles; the original prototype 2 is color-coded in black; the data
points for peptides of series i (3–5) are shown in grey, series ii (6–9) in blue, series iii (10–15) in red, series iv (16–18) in green, and series v (19, 20)
in purple.
Figure 4: D. rerio embryotoxicity of GS 1 and the photoswitchable analogues 2–20 correlated with their in vitro hemolysis [30] for the ring-closed
photoforms (A, filled circles), and for the ring-open photoforms (B, open circles). The compound numbers are shown next to the data points, and the
color code is the same as in Figure 3.
toxicities against zebrafish larvae may correlate with rodent
inhalational toxicities [55], but to the best of our knowledge, no
such comparisons are known for peptides or peptidomimetics.
When plotting the D. rerio embryotoxicity LD50 values of the
ring-open (activated, ON) photoforms against the in vitro HeLa
cytotoxicity indicators, namely against IC50 [30] of the ring-
closed (deactivated, OFF) photoforms (Figure 5A), the data
points are correlated quite well along the diagonal. This corre-
spondence is in contrast to the comparison between hemolysis
and HeLa cytotoxicity (Figure 5B) that had been reported in our
earlier study, where the whole data set shows a systematic devi-
ation off the diagonal. Our new in vivo data, thus shows a much
better correlation of the toxicities between the two tested targets
– epithelial cells of the zebrafish embryo and human malignant
epithelial cells. Erythrocytes, on the other hand, are clearly less
suitable and constitute less representative cells to predict toxic
effects in humans. We can therefore expect an even lower in
Beilstein J. Org. Chem. 2020, 16, 39–49.
47
Figure 5: Phototherapeutic cytotoxic action against HeLa cells of GS 1 and its photoswitchable analogues 2–20, correlated with the new in vivo
results and earlier in vitro data. For each peptide, the HeLa cytotoxic concentrations of the ring-open photoforms (IC50(open)) are plotted against the
corresponding in vivo toxicities to D. rerio embryos (A, LD50(closed)24h), or against the in vitro hemolytic activities (B, HC50(closed), i.e., 50% hemol-
ysis]) of the ring-closed photoforms. The compound numbers are shown next to the data points. The in vitro data is from [30]. Values for the parent
peptide 1 are marked black, and a white filling highlights the initial prototype 2. Color codes for the remaining peptides are the same as in Figure 3.
vivo anticancer selectivity of our peptides than we had previ-
ously judged from the in vitro data on erythrocytes and HeLa
cells. Thus, a further increase of the phototherapeutic indices by
compound modifications is appropriate. Amongst the most
selective compounds against cancer cells, the modifications
implemented in series i, ii and iii are the most effective strate-
gies so far to enhance the phototherapeutic indices. The present
evaluation identifies peptides 2, 4, 7, 8, and 13 as the best
candidates in terms of the phototherapeutic index.
Conclusion
In this study, we have synthesized 19 photoswitchable membra-
nolytic peptides, derived from the cyclic parent gramicidin S.
The two photoforms of these dithienylethene-modified peptides
showed different retention times in reversed-phase HPLC, with
the ring-open forms being more hydrophobic. An in vivo toxici-
ty assay (using two approaches, giving essentially the same
results) was established in order to study the in situ photoactiva-
tion of these peptides using a zebrafish embryo model. We
systematically evaluated the toxicities of the two photoforms
and found that the activated ring-open isomers of our peptides
are more toxic than the inactivated ring-closed isomers, with up
to two orders of magnitude difference. The most promising
modifications of GS appear to be those where a single
uncharged polar amino acid has been introduced on the hydro-
philic face of the peptide.
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